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S U M M A R Y
Objectives: To characterize hepatitis C virus (HCV) epidemiology and inform public health research,
policy, and programming priorities in Afghanistan.
Methods: Records of HCV incidence and prevalence were reviewed systematically and synthesized
following PRISMA guidelines. Meta-analyses were implemented using a DerSimonian–Laird random
effects model with inverse variance weighting to estimate HCV prevalence among various at risk
populations. A risk of bias assessment was incorporated.
Results: The search identiﬁed one HCV incidence and 76 HCV prevalence measures. HCV incidence was
only assessed among people who inject drugs (PWID), and was reported at 66.7 per 100 person-years.
Meta-analyses estimated HCV prevalence at 0.7% among the general population (range 0–9.1%, 95%
conﬁdence interval (CI) 0.5–0.9%), 32.6% among PWID (range 9.5–70.0%, 95% CI 24.5–41.3%), and 2.3%
among populations at intermediate risk (range 0.0–8.3%, 95% CI 1.3–3.7%). No data were available for
other high risk populations such as hemodialysis, thalassemia, and hemophilia patients.
Conclusions: HCV prevalence among the general population in Afghanistan is comparable to global
levels. Data are needed for the level of infection among key clinical populations at high risk of infection.
There is also an immediate need for expansion of harm reduction programs among PWID and prisoners.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen associated
with several morbidities and mortality.1,2 The recent innovations
in HCV treatment and prevention provide opportunities for
achieving substantial reductions in HCV transmission and associ-
ated disease burden.3–5
In some countries of the Middle East and North Africa (MENA)
region, notably Egypt6,7 and Pakistan,8,9 HCV is endemic at high
levels. The state of the infection remains poorly understood in most
other MENA countries including Afghanistan. Here, the decades of
political unrest and military conﬂicts, and the thriving opiates
industry,10 suggest a vulnerability for the transmission of blood-
borne infections including HCV.* Corresponding author. Tel.: +974 4492-8443; fax: +974 4492-8422.
E-mail address: hsc2001@qatar-med.cornell.edu (H. Chemaitelly).
http://dx.doi.org/10.1016/j.ijid.2015.09.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).This work aims at characterizing HCV epidemiology in
Afghanistan. The speciﬁc objectives are: (1) to systematically
review and synthesize all available published and unpublished
records of HCV incidence and prevalence among different
population groups, and (2) to estimate the population-level
HCV prevalence by pooling available HCV prevalence measures
among the general population. This study is conducted under the
umbrella of the MENA HCV Epidemiology Synthesis Project, an
ongoing effort to characterize HCV epidemiology and inform key
public health research, policy, and programming priorities in
MENA.6,11–17
2. Methods
The methodology for this work was adapted from a recently
published protocol for a systematic review of HCV incidence and
prevalence measures for countries in the Horn of Africa subregion
of MENA.11,17ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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All HCV incidence and prevalence records in Afghanistan were
reviewed systematically following the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA) guidelines
(Supplementary Material, Table S1).18 To this end, PubMed,
EMBASE, the World Health Organization Index Medicus for the
Eastern Mediterranean Region database, and the abstract archives
of the International AIDS Society conferences were surveyed, up to
March 16, 2015. Additional records of HCV prevalence were
identiﬁed through the MENA HIV/AIDS Epidemiology Synthesis
Project database.19,20 HCV prevalence measures were also
obtained from the Afghanistan National Blood Safety and
Transfusion Services (i.e., the Central Blood Bank) in Kabul, the
capital of Afghanistan.21 Broad search criteria were used, with no
language restrictions. PubMed and EMBASE were searched using
text terms and medical subject heading (MeSH)/EMTREE terms
exploded to cover all subheadings (Supplementary Material,
Figure S1). The search was restricted to articles published starting
from 1989, the year in which HCV and its antibodies were ﬁrmly
characterized.22,23
2.2. Study selection
Duplicate publications were excluded from the list of identiﬁed
records using a reference manager, Endnote. The titles and
abstracts of remaining records were screened for relevance, and
full-texts of articles deemed relevant or potentially relevant were
retrieved for further screening. The references of all identiﬁed full-
text articles and reviews of the literature were also checked to
identify additional articles that could have been potentially
missed. Any document reporting antibody measures for HCV
incidence and/or prevalence based on primary data qualiﬁed for
inclusion in the review (Figure 1). The exclusion criteria included
case reports, case series, editorials, letters to the editor, commen-
taries, studies referring to hepatitis C as non-A non-B hepatitis, and
records of HCV occurrences among non-Afghan military personnel
stationed in Afghanistan for speciﬁed time periods. A secondary
independent screening was further performed to identify articles
reporting HCV genotype information irrespective of their inclusion
of HCV incidence and/or prevalence measures.
In this work, a ‘report’ refers to a document containing outcome
measures of interest, while a ‘study’ refers to all details pertaining
to a speciﬁc outcome measure. Accordingly, one report could
contribute multiple studies, and multiple reports of the same
study, after being identiﬁed as duplicates, are considered as one
study.
2.3. Data extraction and data synthesis
Data from relevant reports were extracted by the ﬁrst author
(HC). To check for consistency, 50% of the reports were double-
extracted by another co-author (SM). The extracted information
included the following: author(s), full citation, year(s) of data
collection, publication type, country of survey (a few studies were
conducted among Afghan nationals residing outside Afghanistan),
city, study site, study design, study sampling procedure, study
population and its characteristics (sex, age, etc.), sample size,
antibody measures of HCV incidence and/or prevalence (primary
outcomes), and information related to the ascertainment of the
infection. Data on HCV RNA incidence and/or prevalence were
extracted and indicated whenever these were available in reports
including primary outcome measure(s). Decimal places of preva-
lence ﬁgures were included as reported in the original reports.
Prevalence ﬁgures with more than one decimal place were
rounded to one decimal place, with the exception of those below0.1%. Risk factors for HCV infection were extracted only when these
were identiﬁed as signiﬁcant after controlling for confounders
through multivariable regression analyses. Studies reporting HCV
genotypes and subtypes identiﬁed through the independent
secondary screening were extracted to a separate data ﬁle. All
data were extracted to IBM SPSS v. 22.0 (IBM Corp., Armonk, NY,
USA).24
The extracted data were then synthesized by populations’ risk
of acquiring HCV, deﬁned as follows: (1) Populations at low risk:
these comprise blood donors, pregnant women, children, refugees,
and national army recruits, among others. It was assumed here
that HCV prevalence among populations at low risk provides the
best estimate for HCV prevalence in the population at large, i.e., the
general population. Accordingly, in this article, the terms
‘populations at low risk’ and ‘general population’ are used
interchangeably. (2) Populations at intermediate risk: these
comprise healthcare workers, household contacts of HCV infected
patients, hospitalized populations, female sex workers, men who
have sex with men, prisoners, and road transport workers (a
population whose risk of exposure to HCV infection is uncertain
and could be overlapping with other key populations at risk such as
injecting and non-injecting drug users), among others.19 (3)
Populations at high risk: these comprise people who inject drugs
(PWID), and hemodialysis, thalassemia, and hemophilia patients,
among others.
The classiﬁcation of risk was informed by the HCV epidemiolo-
gy literature25–27 and a previously published classiﬁcation.12,14
2.4. Quantitative analysis
HCV prevalence levels were stratiﬁed by populations’ risk
(Tables 1 and 2) and summarized using reported ranges. A
descriptive analysis of HCV genotype and subtype information was
also performed. The diversity of HCV genotype data was assessed
using Shannon Diversity Index.28 Meta-analyses were conducted
for the low, high, and intermediate risk populations (Table 3;
Supplementary Material, Figure S2). The national population-
level HCV prevalence was estimated using the mean HCV
prevalence among the populations at low risk. Studies comprising
a minimum of 25 participants were considered eligible for
inclusion in the meta-analysis. HCV prevalence for the total
sample was replaced with reported stratiﬁed measures whenever
the sample size requirement was fulﬁlled at the level of each
stratum. Stratiﬁcations were considered using a pre-deﬁned
sequential order that prioritizes nationality, followed by popula-
tion, sex, year, region, and age. Only one ﬁnal stratiﬁcation per
study was included to avoid double-counting.
The variance of the prevalence measures was stabilized using
the Freeman–Tukey type arcsine square-root transformation.29
Estimates for HCV prevalence were weighted using the inverse
variance method and then pooled using a DerSimonian–Laird
random effects model.30 This model accounts for the sampling
variation as well as the heterogeneity in HCV prevalence
estimates.30 An assessment of heterogeneity in prevalence
estimates was conducted using several measures: Cochran’s Q
statistic to test for evidence of heterogeneity across these
estimates,30,31 I2 and its conﬁdence interval (CI) to assess the
magnitude of between-study variation that is due to differences in
these estimates across studies rather than chance,30 t2 to estimate
the between-study variance of the true HCV prevalence mea-
sures,30 and the prediction interval to estimate the 95% interval in
which the true prevalence in a new HCV study will lie.30 Statistical
analyses were performed using IBM SPSS v. 22.024 and R v.
3.1.2 software.32
Since a large fraction of HCV prevalence measures in the general
population were among blood donors (Table 1), a sensitivity
Figure 1. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) incidence and prevalence in Afghanistan, adapted from the PRISMA
2009 guidelines.
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normally healthy population on the pooled estimate for HCV
prevalence among the general population. A sensitivity analysis
was also conducted, in which blood donor data collected at the
provincial level were excluded due to their potential contribution
to the national HCV testing data reported by the Afghanistan
National Blood Safety and Transfusion Services.
2.5. Quality assessment
The quality of HCV prevalence measures was determined by
assessing the risk of bias for each study using the Cochrane
approach,33 and by evaluating the precision of the reported
measures (Table 4; Supplementary Material, Tables S2 and S3).
Study appraisal into low vs. high risk of bias was determined using
each of the following three quality domains: the type of HCV
ascertainment (biological assay vs. self-report), the rigor of thesampling methodology (probability-based vs. convenience sam-
pling), and the response rate (80% or 80% of the target sample
size was reached for studies using respondent-driven sampling vs.
otherwise). For example, a study where the infection has been
ascertained using a biological assay would be classiﬁed as having
‘low risk of bias’ for the ‘type of HCV ascertainment’ quality domain.
Studies with missing information for any of the domains were
classiﬁed as having an unclear risk of bias for that speciﬁc domain.
HCV measures among individuals presenting voluntarily to facilities
where routine blood screening is conducted, or that were retrieved
from patients’ medical records, were considered as having a low risk
of bias for the ‘response rate’ domain. HCV prevalence measures
generated through country-level routine reporting, with limited
description of methods to be able to conduct a risk of bias
assessment, were considered of unknown quality. Studies were
considered as having high precision if the number of HCV tested
individuals was at least 100 participants. For an HCV prevalence of
Table 1
Studies reporting hepatitis C virus (HCV) prevalence among populations at low risk (general population) in Afghanistana
Author, year (citation) Year(s)
of data
collection
City or country
of survey
Study site Study
design
Study
sampling
procedure
Population Sample size HCV
prevalence
(%)
HCV RNA
prevalence
among
antibody
positive (%)
Populations at low risk (general population; number of studies = 46)
Dupire et al., 199941 1995–96 Kabul Central Blood Bank CS Conv Blood donors 1081 0.3
Khan et al., 201137 1996 Central Blood Bank CS Conv Blood donors 5309 0.1
Khan et al., 201137 1997 Central Blood Bank CS Conv Blood donors 3942 0.3
Khan et al., 201137 1998 Central Blood Bank CS Conv Blood donors 4221 0.4
Khan et al., 201137 1999 Central Blood Bank CS Conv Blood donors 7964 0.2
Central Blood Bank, 201521 2000 Central Blood Bank CS Conv Blood donors 3136 0
Central Blood Bank, 201521 2001 Central Blood Bank CS Conv Blood donors 9974 0.02
Central Blood Bank, 201521 2002 Central Blood Bank CS Conv Blood donors 11 276 0.6
Khan et al., 201137 2002 Parwan Blood bank (province) CS Conv Blood donors 581 0
Khan et al., 201137 2002 Mazar-i-Sharif Blood bank (province) CS Conv Blood donors 964 0
Central Blood Bank, 201521 2003 Central blood bank CS Conv Blood donors 18 673 0.9
Khan et al., 201137 2003 Nangarhar Blood bank (province) CS Conv Blood donors 3629 1.6
Khan et al., 201137 2003 Mazar-i-Sharif Blood bank (province) CS Conv Blood donors 4714 0
Central Blood Bank, 201521 2004 Central blood bank CS Conv Blood donors 26 318 1.1
Khan et al., 201137 2004 Nangarhar Blood bank (province) CS Conv Blood donors 3525 2.6
Khan et al., 201137 2004 Baghlan Blood bank (province) CS Conv Blood donors 232 0
Khan et al., 201137 2004 Mazar-i-Sharif Blood bank (province) CS Conv Blood donors 2147 0.05
Khan et al., 201137 2004 Herat Blood bank (province) CS Conv Blood donors 2890 0.1
Khan et al., 201137 2004 Jowzjan Blood bank (province) CS Conv Blood donors 1264 0.08
Khan et al., 201137 2004 Logar Blood bank (province) CS Conv Blood donors 888 0.6
Khan et al., 201137 2004 Badakhshan Blood bank (province) CS Conv Blood donors 256 0.4
Central Blood Bank, 201521 2005 Central blood bank CS Conv Blood donors 30 351 1.5
Khan et al., 201137 2005 Nangarhar Blood bank (province) CS Conv Blood donors 2145 6.9
Khan et al., 201137 2005 Herat Blood bank (province) CS Conv Blood donors 2185 1.0
Khan et al., 201137 2005 Mazar-i-Sharif Blood bank (province) CS Conv Blood donors 1190 0.6
Khan et al., 201137 2005 Jowzjan Blood bank (province) CS Conv Blood donors 584 7.2
Khan et al., 201137 2005 Parwan Blood bank (province) CS Conv Blood donors 168 4.8
Khan et al., 201137 2005 Kunar Blood bank (province) CS Conv Blood donors 11 9.1
Khan et al., 201137 2005 Kandahar Blood bank (province) CS Conv Blood donors 1867 0.1
Khan et al., 201137 2005 Kunduz Blood bank (province) CS Conv Blood donors 826 1.9
Central Blood Bank, 201521 2006 Central blood bank CS Conv Blood donors 37 024 2.0
Central Blood Bank, 201521 2007 Central blood bank CS Conv Blood donors 39 402 1.8
Central Blood Bank, 201521 2008 Central blood bank CS Conv Blood donors 43 769 1.5
Central Blood Bank, 201521 2009 Central blood bank CS Conv Blood donors 36 447 1.2
Central Blood Bank, 201521 2010 Central blood bank CS Conv Blood donors 52 698 1.1
Central Blood Bank, 201521 2011 Central blood bank CS Conv Blood donors 74 820 0.8
Central Blood Bank, 201521 2012 Central blood bank CS Conv Blood donors 70 820 0.9
Central Blood Bank, 201521 2013 Central blood bank CS Conv Blood donors 83 802 0.6
Central Blood Bank, 201521 2014 Central blood bank CS Conv Blood donors 95 940 0.6
Central Blood Bank, 201521 2015 Central blood bank CS Conv Blood donors 30 510 0.4
Afghanistan NACP, 201036 2008–09 Mixed VCT CS Conv Blood donors 19 875 3.0
Pehlivanoglu et al., 201144 2009 Turkey Hospital CS Conv Asylum seekers 124 4
Richter et al., 201445 2011 Arnhem and
Rheden,
Netherlands
Community CS Conv First-generation
immigrants
293 1 0
Tanju et al., 201446 2012 Kabul Outpatient clinics CS Conv Children aged
1–15 years
330 0.6
Todd et al., 201247 2010–12 Kabul Military training center CS SRS Afghan national
army recruits and
national police
trainees
6849 0.7
Todd et al., 200848 2006 Kabul Hospital CS Conv Pregnant women 4452 0.3
Conv, convenience; CS, cross-sectional; NACP, National AIDS Control Program; SRS, simple random sampling; VCT, voluntary counseling and testing center.
a The decimal places in the prevalence ﬁgures are as reported in the original reports, but prevalence ﬁgures with more than one decimal place are rounded to one decimal
place, with the exception of those below 0.1%.
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0–5%, a reasonable CI for an HCV prevalence estimate.
3. Results
3.1. Search results
Figure 1 describes the process of study selection based on
PRISMA guidelines.18 A total of 135 citations were identiﬁed:
29 through PubMed, 49 through EMBASE, and 57 through
international and regional databases. A total of 26 reports wereidentiﬁed as relevant or potentially relevant after removing
duplicates and screening the titles and abstracts of the remaining
records. Four additional country-level reports34–38 and ﬁve other
HCV prevalence measures (generated through routine reporting)
were identiﬁed through the MENA HIV/AIDS Epidemiology
Synthesis Project database.19 Sixteen HCV prevalence measures
were further obtained from the Afghanistan National Blood Safety
and Transfusion Services for the time period 2000–2015.21
Out of all of these records, 14 reports and one HCV prevalence
measure were excluded for the following reasons: not meeting the
eligibility criteria, the full-text or abstract (if the full-text was not
Table 2
Studies reporting hepatitis C virus (HCV) prevalence among populations at high and intermediate risk in Afghanistana
Author, year (citation) Year(s) of data
collection
City or country
of survey
Study
site
Study
design
Study
sampling
procedure
Population Sample
size
HCV
prevalence
(%)
HCV RNA prevalence
among antibody
positive (%)
Populations at high risk (number of studies = 14)
Afghanistan NACP, 201034 2009 Herat CS RDS PWID 159 57.9
Afghanistan NACP, 201034 2009 Kabul CS RDS PWID 286 37.1
Afghanistan NACP, 201034 2009 Mazar-i-Sharif CS RDS PWID 102 25.5
MENA ESP, 201119 2011 PWID 4866 15.7
Afghanistan NACP, 201235 2012 Charikar CS RDS PWID 117 25.0
Afghanistan NACP, 201235 2012 Herat CS RDS PWID 185 70.0
Afghanistan NACP, 201235 2012 Jalalabad CS RDS PWID 236 9.5
Afghanistan NACP, 201235 2012 Kabul CS RDS PWID 369 27.6
Afghanistan NACP, 201235 2012 Mazar-i-Sharif CS RDS PWID 254 18.8
Nasir et al., 201149,52 2006–08 Herat VCT CS Conv PWID 340 49.1 58.2
Nasir et al., 201149,52 2006–08 Jalalabad VCT CS Conv PWID 96 12.5 41.7
Nasir et al., 201149,52 2006–08 Mazar-i-Sharif VCT CS Conv PWID 187 24.1 59.1
Todd et al., 200751 2005–06 Kabul VCT CS Conv PWID 458 36.9
Todd et al., 201150 2007–09 Kabul CS Conv PWID 483 36.1
Populations at intermediate risk (number of studies = 16)
Afghanistan NACP, 201034 2009 Herat Prison CS SysRS Prisoners 317 4.1
Afghanistan NACP, 201034 2009 Kabul Prison CS SysRS Prisoners 352 1.7
Afghanistan NACP, 201034 2009 Kabul CS RDS FSWs 368 0.8
Afghanistan NACP, 201034 2009 Torkham Border
checkpoint
CS SysRS Road
transport
workers
365 6.8
MENA ESP, 201119 2011 FSWs 440 5.4
MENA ESP, 201119 2011 MSM 555 8.3
MENA ESP, 201119 2011 Prisoners 1024 1.0
Afghanistan NACP, 201235 2012 Herat CS RDS FSWs 344 0.6
Afghanistan NACP, 201235 2012 Herat Prison CS SysRS Prisoners 351 1.4
Afghanistan NACP, 201235 2012 Kabul CS RDS FSWs 333 0
Afghanistan NACP, 201235 2012 Kabul CS RDS MSM 207 5.3
Afghanistan NACP, 201235 2012 Kabul Prison CS SysRS Prisoners 368 4.6
Afghanistan NACP, 201235 2012 Mazar-i-Sharif CS RDS FSWs 355 1.7
Afghanistan NACP, 201235 2012 Torkham Border
checkpoint
CS SysRS Road
transport
workers
378 1.8
Todd et al., 201053 2006–08 Mixed (Jalalabad,
Kabul and
Mazar-i-Sharif)
CS Conv FSWs 520 1.9
Vahdani et al., 200654 Tehran, Iran CS Conv Street
children
79 0
Conv, convenience; CS, cross-sectional; FSWs, female sex workers; MENA ESP, Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database; MSM, men
who have sex with men; NACP, National AIDS Control Program; PWID, people who inject drugs; RDS, respondent-driven sampling; SysRS, systematic random sampling; VCT,
voluntary counseling and testing center.
a The decimal places in the prevalence ﬁgures are as reported in the original reports, but prevalence ﬁgures with more than one decimal place are rounded to one decimal
place, with the exception of those below 0.1%.
H. Chemaitelly et al. / International Journal of Infectious Diseases 40 (2015) 54–6358available) not including data on relevant indicators, or being a
duplicate of another study included in the review. Since different
sources provided data on HCV prevalence among blood donors
from the Central Blood Bank,19,21,37–41 and to avoid potential
duplication, the data obtained directly from the Afghanistan
National Blood Safety and Transfusion Services were used
whenever these were available, i.e., for the time period 2000–
2015.21 These data had nearly always the largest sample size for
HCV testing. These measures were complemented by blood donor
data obtained from other sources,37,41 such as Khan et al. covering
the time period prior to 2000 or reporting HCV prevalence at the
provincial level.37 The latter were included to ensure a broader
geographical representation of HCV prevalence data in
Afghanistan, even though this provincial HCV testing may have
been accounted for in the national compilation of HCV testing data
among blood donors as reported by the Afghanistan National Blood
Safety and Transfusion Services. A sensitivity analysis was
however conducted to assess the consequences of any potential
duplication (see section 3.5, Sensitivity analyses). An article on the
2009 Integrated Bio-Behavioral Surveillance Survey (IBBSS)42 was
also replaced by the actual full report of this survey,34 for a more
complete description of the study. In summary, 16 eligible reports
and 20 other HCV prevalence measures from country-level datawere included in the systematic review. These yielded one HCV
incidence and 76 HCV prevalence measures.
The independent secondary screening for HCV genotype data
yielded one record reporting a single HCV genotype study measure.
3.2. HCV incidence overview
Only one incidence study was identiﬁed, reporting an HCV
incidence rate of 66.7 per 100 person-years (95% CI 55.9–77.5) in a
cohort of 298 PWID recruited in Kabul between the years 2007 and
2009 and followed for 6 months.43
3.3. HCV prevalence overview
3.3.1. Among the general population
The search identiﬁed 46 studies among the general population
(Table 1). The majority of studies were retrieved from the records
of the Central Blood Bank in Kabul and its provincial branches.
Among blood donors (number of studies (n) = 41), HCV prevalence
ranged from 0 to 9.1%.21,36,37,41 Two studies among Afghan asylum
seekers in Turkey and Afghan ﬁrst-generation immigrants to the
Netherlands reported HCV prevalence at 4%44 and 1%,45 respec-
tively. HCV prevalence levels of less than 1% were generally
Table 3
Findings of the meta-analyses for hepatitis C virus (HCV) prevalence measures stratiﬁed by population risk of exposure in Afghanistan
Populations at risk Studies Samples Reported
prevalence
HCV prevalence
estimates
Heterogeneity measures t2
Total n Total n Range (%) Mean (%) 95% CI Q (p-value)a t2 b I2% (conﬁdence
limits)c
Prediction
interval (%)d
Populations at low risk
(general population)
47 749 466 0–9.1 0.7 0.5–0.9 3089.1
(p < 0.0001)
0.0044 98.5 (98.3–98.7) 0.0–2.3
Populations at high risk
(all studies were among PWID)
14 8139 9.5–70.0 32.6 24.5–41.3 669.6
(p < 0.0001)
0.1276 97.8 (97.2–98.2) 4.3–71.3
Populations at intermediate risk 16 6356 0–8.3 2.3 1.3–3.7 139.2
(p < 0.0001)
0.0211 89.2 (84.1–92.7) 0.0–9.8
CI, conﬁdence interval; PWID, people who inject drugs.
a Q: the Cochran Q statistic is a measure assessing the existence of heterogeneity in HCV prevalence estimates.
b t2: the estimated between-study variance in the double arcsine transformed proportions of the true HCV prevalence estimates. The back-transformed t2 was not
calculated as the methodology to do so is not currently available.
c I2: a measure assessing the magnitude of between-study variation that is due to differences in HCV prevalence estimates across studies rather than chance.
d Prediction interval: estimates the 95% interval in which the true HCV prevalence in a new HCV study will lie.
Table 4
Summary of precision and risk of bias assessment for the hepatitis C virus (HCV)
incidence and prevalence measures extracted from eligible reports
Quality assessment HCV incidence HCV prevalence
Number of
studies
% Number of
studies
%
Precision of estimates
High precision 1 100 73 96.1
Low precision 0 0 3 3.9
Risk of bias quality domains
HCV ascertainment
Low risk of bias 32 100
High risk of bias 0 0
Sampling methodology
Low risk of bias 20 62.5
High risk of bias 12 37.5
Response rate
Low risk of bias 19 59.4
High risk of bias 5 15.6
Uncleara 8 25.0
Total studies where risk
of bias assessment was possible
32 42.1
Unknownb 1 100 44 57.9
Total studies 1 100 76 100
Summary of risk of bias assessment for
HCV prevalence measures
Number of studies %
Low risk of bias
In at least one quality domain 32 100
In at least two quality domains 23 71.9
In all three quality domains 16 50.0
High risk of bias
In at least one quality domain 16 50.0
In at least two quality domains 1 3.1
In all three quality domains 0 0
Total studies where risk of bias
assessment was possible
32 42.1
Total studies 76 100
a Studies with missing information for any of the domains were classiﬁed as
having an unclear risk of bias for that speciﬁc domain.
b Studies extracted through country-level routine reporting, with a limited
description of the sample not permitting the risk of bias assessment to be
conducted, were classiﬁed as being of unknown quality.
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army recruits and national police trainees (0.7%),47 and pregnant
women (0.3%).48
3.3.2. Among populations at high risk
All 14 studies among populations at high risk were among
PWID (Table 2). HCV prevalence in this population ranged from
9.5% to 70.0%,19,34,35,49–51 with regional and temporal variation. Inone study from various parts of Afghanistan, HCV prevalence was
reported at 15.7%.19
HCV prevalence among PWID was also measured in a series of
city-speciﬁc studies. In Herat, HCV prevalence was ﬁrst assessed in
a convenience sample at 49.1% in 2006–08.49 In 2009, in the ﬁrst
round of the IBBSS using respondent-driven sampling, HCV
prevalence was measured at 57.9%.34 A prevalence of 70.0% was
subsequently reported in this city during the second round of the
IBBSS in 2012.35 In Charikar, HCV prevalence was reported at 25.0%
in the only IBBSS round in this city in 2012.35
An apparent trend of somewhat declining HCV prevalence was
observed among PWID in three cities. In Kabul, HCV prevalence
was assessed at 36.9%51 and 36.1%50 in convenience samples in
2005–06 and 2007–09, respectively, and at 37.1% in the ﬁrst IBBSS
round in 2009.34 The second IBBSS round in 2012 reported HCV
prevalence at 27.6%.35 In Mazar-i-Sharif, HCV prevalence declined
from 24.1% in a convenience sample in 2006–0849 and 25.5% in the
ﬁrst IBBSS round in 2009,34 to 18.8% in the second IBBSS round in
2012.35 In Jalalabad, HCV prevalence declined from 12.5% in a
convenience sample in 2006–0849 to 9.5% in the only IBBSS round
in this city in 2012.35
HCV RNA prevalence was measured only among PWID in
Afghanistan. HCV RNA prevalence among HCV antibody positive
individuals was reported at 58.2% in Herat,52 41.7% in Jalalabad,52
and 59.1% in Mazar-i-Sharif (Table 2).52
3.3.3. Among populations at intermediate risk
A total of 16 studies were identiﬁed for populations at
intermediate risk (Table 2). Among prisoners (n = 5), HCV
prevalence ranged from 1% to 4.6%.19,34,35 Among men who have
sex with men, HCV prevalence was reported at 8.3%19 and 5.3%.35
Among female sex workers (n = 6), HCV prevalence ranged from
0 to 5.4%.19,34,35,53 Among road transport workers recruited at a
border checkpoint, HCV prevalence was reported at 6.8%34 and
1.8%.35 A study among Afghan street children in Tehran, Iran,
measured HCV prevalence at 0%.54
3.4. Pooled mean HCV prevalence estimates
Table 3 summarizes the ﬁndings of the meta-analyses for HCV
prevalence among the general, high, and intermediate risk
populations in Afghanistan. The pooled estimate for the national
population-level HCV prevalence, based on pooling the measures
for the populations at low risk (general population), was 0.7%
(95% CI 0.5–0.9%). The prediction interval, that is the estimated
95% interval range for the true effect size (HCV prevalence)
across studies, was 0–2.3%. There was signiﬁcant evidence for
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was estimated at 98.5% (95% CI 98.3–98.7%) indicating that most
variation across studies was due to differences in HCV prevalence
estimates rather than chance.
Pooled HCV prevalence for populations at high risk (all of whom
were PWID) was estimated at 32.6% (95% CI 24.5–41.3%). The
prediction interval was 4.3–71.3%. There was signiﬁcant evidence
for heterogeneity in HCV prevalence estimates (p-value <0.0001).
I2 was estimated at 97.8% (95% CI 97.2–98.2%); most variation
across studies was due to differences in HCV prevalence estimates.
Pooled HCV prevalence for populations at intermediate risk was
estimated at 2.3% (95% CI 1.3–3.7%). The prediction interval was 0–
9.8%. There was signiﬁcant evidence for heterogeneity in HCV
prevalence estimates (p-value <0.0001). I2 was estimated at 89.2%
(95% CI 84.1–92.7%); most variation across studies was due to
differences in HCV prevalence estimates.
Forest plots for all HCV prevalence meta-analyses can be found
in the Supplementary Material (Figure S2).
3.5. Sensitivity analyses
The pooled estimate for the national population-level HCV
prevalence, after excluding blood donor data, was 0.6% CI (95% CI
0.2–1.2%). The prediction interval was 0–2.7% and there was
signiﬁcant evidence for heterogeneity in HCV prevalence estimates
(p-value <0.001). I2 was estimated at 76.9% (95% CI 48.5–89.6%);
most variation across studies was due to differences in HCV
prevalence estimates rather than chance.
The exclusion of blood donor data collected at the provincial
level also did not impact the pooled estimate for the national
population-level HCV prevalence, which was assessed at 0.7% (95%
CI 0.5–0.9%). Here, the prediction interval was 0.02–2.1% and there
was also signiﬁcant evidence for heterogeneity in HCV prevalence
estimates (p-value <0.0001). I2 was estimated at 98.5% (95% CI
98.3–98.7%); most variation across studies was also due to
differences in HCV prevalence estimates rather than chance.
3.6. HCV genotypes
Only one study reported HCV genotype information among
71 HCV RNA positive PWID recruited from Herat, Mazar-i-Sharif,
and Jalalabad between 2006 and 2008.55 There were no individuals
infected with multiple HCV genotypes. About two-thirds of
participants (44 individuals) were infected with genotype 3a,
while the rest were infected with genotype 1. Subtypes 1a and 1b
were found among 92.6% and 7.4%, respectively, of infected
persons with genotype 1. Genotypes 3a, 1a, and 1b constituted
66%, 31.9%, and 2.1%, respectively, of HCV infections in Herat
(number of samples = 47), and 52.2%, 43.5% and 4.3%, respectively,
of infections in Mazar-i-Sharif (number of samples = 23). The only
HCV infected individual in Jalalabad had genotype 3a.
3.7. Risk factors for HCV infection
Only two studies assessed risk factors for HCV exposure using
multivariable regression analyses, and both studies were among
PWID in Kabul.50,56 Reported risk factors included ever sharing a
needle or syringe, injecting career duration, frequency of daily
injections, heroin use, initiation of drug injection outside
Afghanistan, ever having an abscess at the injecting site,
unemployment, and age.
3.8. Quality assessment of HCV incidence and prevalence measures
Findings of the quality assessment are summarized in
Table 4. The only identiﬁed HCV incidence measure and the vastmajority of HCV prevalence measures (96.1%) were based on
samples including at least 100 participants, and thus were
classiﬁed as having high precision. The risk of bias assessment
was possible for 32 out of the 76 HCV prevalence measures. The
only identiﬁed HCV incidence measure and 44 HCV prevalence
measures were judged of unknown quality given the limited
sample description. These were excluded from further analyses. It
is worth noting, however, that the vast majority of these studies
with unknown risk of bias were based on testing among blood
donors reported by blood banks across Afghanistan.21,37
HCV ascertainment for all remaining prevalence measures
(after excluding those with an unknown risk of bias) was based on
biological assays; no study used self-report for HCV ascertainment.
About a third of the samples (28.1%) underwent second
conﬁrmatory testing, with almost all using the more sensitive
and speciﬁc recombinant immunoblot assay (RIBA). For most
studies (75.0%), information about the generation of the assay used
was missing. The rest of the studies reported the use of the more
sensitive and speciﬁc third-generation assays. About a third of the
studies (37.5%), including the vast majority of those conducted
among the general population, were drawn using convenience
sampling. Two-thirds of the studies (59.4%) had a low risk of bias in
the response rate domain, while 15.6% had a high risk of bias.
Response rate information was missing for 25.0% of the measures.
In summary, the HCV prevalence measures were of reasonable
quality. All studies had a low risk of bias in at least one quality
domain, and 71.9% had a low risk of bias in at least two of the three
quality domains. Less than 3.1% of studies had a high risk of bias in
two or three quality domains. The study-speciﬁc quality assess-
ment for each prevalence measure can be found in the
Supplementary Material (Tables S2 and S3).
4. Discussion
We presented a systematic review and synthesis of HCV
incidence and prevalence in Afghanistan, and estimated the
national population-level HCV prevalence and the pooled mean
HCV prevalence among PWID and intermediate risk populations.
The results show that the national HCV prevalence in Afghanistan
is at about 1%, although regional variations appear to be present.
This prevalence level is comparable to that observed in most
countries globally,25,57,58 and is also comparable to that in most
other MENA countries including Iran15 and countries of the
Arabian Gulf,13 Maghreb,12 Horn of Africa,16 and Fertile Crescent
(except Egypt)14 subregions of MENA. This estimate is also
comparable to prevalence levels in the adjacent North West
Frontier and Balochistan provinces of Pakistan, where HCV
prevalence is assessed at 1.1% and 1.5%, respectively—the lowest
nationwide in Pakistan (national prevalence reported at 4.8%).8,9,59
The ﬁnding of rather low HCV prevalence among the general
population in Afghanistan may not be surprising in a country with
a rather low level of injecting drug use and where medical care is
under-developed although currently expanding.
A large fraction of HCV prevalence measures in the low risk
populations were among blood donors (Table 1). HCV prevalence
in this normally healthy population may underestimate HCV
prevalence in the population at large.60,61 However, the sensitivity
analysis excluding blood donors yielded an estimate of 0.6% for
HCV prevalence among the general population, thus afﬁrming the
robustness of our pooled estimate of 0.7%. The pooled estimate was
also robust to the exclusion of blood donor data collected at the
provincial level. The latter could have affected our estimate
because of potential duplication, as provincial data may have been
accounted for in the national reported data from the Afghanistan
National Blood Safety and Transfusion Services. Our estimate
however was lower than that reported recently using a different
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1.1% in the study by Gower et al.).26 The difference stems largely
from the inclusion of more studies in generating our estimate
(47 studies for our pooled estimate versus apparently one study in
Gower et al.).26
For many developed countries, HCV incidence seems to be
driven largely by injecting drug use.62–64 Afghanistan is the world’s
largest opiates producer, accounting for over 80% of the global
supply, most of which follows drug trafﬁcking routes through Iran
and Pakistan.10 The population proportion of injecting drug use in
Afghanistan is still poorly known, with estimates ranging from
0.05% to 0.24%, lower than estimates in neighboring MENA
countries.65 The population proportion of injecting drug use in
MENA as a whole is estimated at 0.24%, in the intermediate range
compared to global levels.65 It is possible that the consumption of
reﬁned opiates through injection in Afghanistan may not have
reached the levels observed in neighboring countries given the
wider practice of smoking unreﬁned opium, a less expensive
alternative.10 Injecting drug use appears to have grown in
popularity only after the return of Afghan refugees from
neighboring countries following the fall of the Taliban.50,51 A
recent survey indicated that close to 40% of PWID initiated
injecting drug use while outside Afghanistan.66
One of the strengths of HCV epidemiology evidence in
Afghanistan is the number and geographic coverage of HCV
prevalence surveys among PWID. This is often a shortcoming in
other MENA countries.6,12–14,16 Although substantial, HCV preva-
lence among PWID estimated at 32.6% (Table 3) is lower than that
reported in MENA65,67 and globally.27 There also appears to be
regional variations in prevalence, and that the prevalence may
have declined in parts of Afghanistan in recent years (Table 2). It is
not clear whether this variation may reﬂect the impact of the
recent expansion of harm reduction services in Afghanistan,68 or
may be due to natural HCV epidemic dynamics among recently
formed injecting networks. HCV RNA prevalence among HCV
antibody positive PWID (range 41.7–59.1%; Table 2) was also lower
than expected based on the global literature.69
The large HCV incidence rate measured in a cohort of PWID43
and the considerable HCV prevalence among this population group,
although less than what would be expected for such a high
incidence rate, highlight the need for further expansion of harm
reduction services. The coverage of harm reduction programs
remains low in most provinces,70 such as in Herat where there is
evidence of a large HCV prevalence and an emerging HIV
epidemic.49 It bears notice that most settings with high HCV
prevalence among PWID in Afghanistan have witnessed emerging
and growing HIV epidemics among this population in recent
years.65,67 This afﬁrms the utility of using HCV antibody prevalence
as a biomarker for HIV epidemic potential, as has been demon-
strated recently in an ecological analysis of the empirical
association between HCV prevalence and HIV prevalence in MENA
countries.71 Accordingly, the geographic distribution of HCV
prevalence can be used to inform the expansion of harm reduction
services with public health beneﬁts for both HIV and HCV. Another
population that could beneﬁt from expanding harm reduction
services is prisoners. Drug users are encouraged to follow a
treatment regimen when ﬁrst identiﬁed in Afghanistan; however,
relapse is often penalized by incarceration.70 Close to half of PWID
participating in the 2012 IBBSS reported having been imprisoned.35
Overall, low HCV prevalence was observed among female sex
workers in Afghanistan, likely a consequence of the inefﬁciency of
HCV heterosexual sex transmission72,73 and the low prevalence of
drug injection reported by female sex workers.35 Meanwhile,
rather high HCV prevalence was measured among men who have
sex with men. It is unclear whether this prevalence reﬂects
overlapping risk behavior with drug injection or is due to HCVsexual transmission through anal sex, a mode of transmission that
seems to be of increasing importance.74,75
This review identiﬁed a key gap in our understanding of HCV
epidemiology in Afghanistan. No data were available for key
clinical populations at high risk of infection, such as hemodialysis,
thalassemia, and hemophilia patients. HCV transmission in
healthcare settings has been identiﬁed as a leading mode of
exposure to HCV in MENA countries6,8,12–16 and globally.76 The role
of community-based exposures such as tattooing, cupping, and
medical injections administered by other than healthcare provi-
ders remains unknown. There were also no studies on HCV vertical
transmission. Another gap in evidence is the distribution of HCV
genotypes in Afghanistan. Only one study was identiﬁed to this end
and was among PWID.55 The study reported dominance of
genotype 3—a ﬁnding in line with the association between this
genotype and injecting drug use globally.77
The present systematic review and meta-analyses are limited
by the quantity and quality of available studies, as well as their
representativeness of the different at risk populations. HCV
prevalence studies among the general population were mostly
based on convenience sampling. Findings of the two IBBSS surveys
were also limited to major cities in Afghanistan while excluding
areas of major opiate cultivation, such as Helmand and Kandahar,
for security considerations.34,35
The meta-analyses revealed considerable heterogeneity in HCV
prevalence estimates across studies. Several factors could have
contributed to this heterogeneity, including variability within the
speciﬁc subpopulation studied, sampling methodology and
participant recruitment, sex and age-group representation in the
sample, year of study, location, and assay used.12 With the
relatively small number of outcome measures, it was not possible
to quantify the contribution of these sources of variation to the
heterogeneity in HCV prevalence estimates through a multivari-
able meta-regression analysis.
4.1. Conclusions
HCV prevalence in the population at large in Afghanistan
appears to be around 1%, and is comparable to most countries in
MENA and globally. HCV prevalence among PWID is substantial
with evidence of regional and temporal variation. No data were
available for other high risk populations, such as hemodialysis,
thalassemia, and hemophilia patients. Expansion of HCV research
into these populations is warranted. Conduct of a nationally
representative population-based survey is also recommended to
address several gaps in our understanding of HCV epidemiology in
this country, as has been done recently in Egypt7,78–82 and
Pakistan.8,9 If a national survey is difﬁcult, the survey can cover
only the parts of Afghanistan where the security situation allows.
Estimating the size of, and establishing HCV molecular epidemiol-
ogy among different risk populations, are also needed.
The present ﬁndings inform planning of health service
provision, articulation of HCV policy guidelines, and implementa-
tion of effective HCV programming to reduce HCV transmission
and decrease the burden of its associated diseases. HCV prevention
efforts in Afghanistan should focus on expanding access to and
coverage of harm reduction services among PWID and prisoners.
Adoption of the new World Health Organization guidelines for the
use of safety-engineered syringes could also minimize exposure to
HCV and other blood-borne pathogens.4,5
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